



March 7, 2011

Neil A. Rombardo
Carson City District Attorney
885 East Musser St. #2030
Carson City, NV 89701

Dear Mr. Rombardo,

I am writing to support efforts to establish RX-only status for pseudoephedrine (PSE) throughout the nation. We were dismayed to learn of the Consumer Healthcare Products Association (CHPA) Stop Meth Not Meds <http://www.stopmethnotmeds.com/> campaign and its endorsement by Asthma and Allergy Foundation of America (AAFA). We are compelled to share our views.

PSE relieves symptoms of the common cold; however, it is not a cure nor a life-saving medication. Medical evidence does not support its use to treat life-threatening or debilitating symptoms of allergy and asthma. Unfortunately, more than half of PSE sold in the U.S. is redirected for illegal manufacture of methamphetamine (meth). States must take action to preserve patient access to PSE while protecting citizens from illegal drug trafficking and profiteering. RX-only status for PSE achieves this goal exceedingly well.

Despite CHPA and AAFA's well-funded public relations activities, our office has received no calls or reports from patients asking that we support the Stop Meth Not Meds campaign.

The Stop Meth Not Meds campaign is well written; one could assume that CHPA and states were working together and that supporting the initiative is in their best interest. Nowhere is it apparent that CHPA members are lobbying AGAINST state lawmakers' efforts to serve the public!

CHPA's Stop Meth Not Meds campaign features AAFA's survey, said to represent patient perspectives. However, survey results read very much like CHPA's campaign literature and press. AAFA's online press release directs inquiries for additional information to AAFA's Department of External Affairs or Department of Policy and Programs but fails to mention that the contact's link, [Anna Otten](#) works at Edelman Public Relations not AAFA.

The CHPA campaign, AAFA's survey, press release, policy statements and related materials all fail to mention any of the potential benefits of RX-only PSE status such as:

- Insurance co-pays help offset the cost
- Consumers will likely make more informed purchase decisions
- Less confusion about which brand or generic to use; no temptation to purchase multiple products "in case the first one doesn't work"

- Reduced potential for unintentional overdosing children and elderly patients (by using multiple products containing PSE)
- Patients can use the drive-thru window instead of going inside the store, standing bewildered at the array of cough and cold remedies

RX-only PSE saves lives, whereas PSE/Meth takes and ruins lives, robs children of their youth and destroys families.

Given these benefits, AANMA supports RX-only status for PSE.

Sincerely yours,

A handwritten signature in cursive script that reads "Nancy Sander". The signature is written in dark ink and is positioned above the typed name and title.

Nancy Sander
President and Founder
Allergy & Asthma Network
Mothers of Asthmatics